Intercure Ltd. (INCR) stock
INCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.63−0.16 (-4.22%)
Close on Nov 16, 2026Market cap $198.49MP/E –Yield –
Intercure r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was 390.00K ILS, down 5.8% from the year before. The highest annual figure on record is 1.71M ILS in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 390.00K ILS | -5.8% |
| FY2024 | Dec 31, 2024 | 414.00K ILS | +6.7% |
| FY2023 | Dec 31, 2023 | 388.00K ILS | -38.6% |
| FY2022 | Dec 31, 2022 | 632.00K ILS | -48.8% |
| FY2021 | Dec 31, 2021 | 1.24M ILS | -21.6% |
| FY2020 | Dec 31, 2020 | 1.58M ILS | -7.8% |
| FY2019 | Dec 31, 2019 | 1.71M ILS | – |
See a number that looks wrong?